Mylan

Photo
10.01.2023 • News

Viatris Forms Eye Care Unit from Acquisitions

Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.

Photo
26.11.2020 • News

Upjohn/Mylan Merger Closes to Form Viatris

Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer stockholders owned about 57% of the outstanding shares of Viatris common stock and Mylan shareholders owned roughly 43%.

Photo
21.09.2020 • News

Mylan Buys Aspen’s European Thrombosis Assets

Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company will use proceeds from the sale to pay down debt.

Photo
04.07.2020 • News

Mylan Invests Again in Mapi’s MS Therapy

US generics specialist Mylan is investing an additional $20 million in Mapi Pharma to support the latter’s ongoing Phase 3 clinical study and eventual commercialization of Glatiramer Acetate (GA) Depot for treating patients with relapsing-remitting multiple sclerosis (RRMS) in the US.

22 more articles

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.